1 / 48

Medical Immunology

Medical Immunology. Department of Immunology. Yiwei Chu. Chapter 17. Immunity to tumors. June, 21, 2010. Content. 1. General Features. 2. Tumor antigen. 3. Immune Responses. 4. Evasion of Immune Responses. 5. Immunotherapy.

dolph
Télécharger la présentation

Medical Immunology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medical Immunology Department of Immunology Yiwei Chu

  2. Chapter 17 Immunity to tumors June, 21, 2010

  3. Content 1. General Features 2. Tumor antigen 3. Immune Responses 4. Evasion of Immune Responses 5. Immunotherapy

  4. Cancer is a major health problem worldwide and one of the most important causes of morbidity and mortality in children and adults.

  5. Robin Bush The sister of George W. Bush, die from leukemia, at the age of 4. Walt Disney This famous animator, producer and co-founder of the corporation known as The Walt Disney Company died at the age of 65 from lung cancer, making him one of the most famous celebrities to have died from smoking. Paul Newman Paul Newman was of course a great actor, but was known well for his healthy line of food. He struggled with lung cancer, and passed away on September 26, 2008,at the age of 83.

  6. General Features • Tumor express antigens that are recognized as foreign by the immune system of the tumor-bearing host. • Immune responses frequently fail to prevent the growth of tumors. • The immune system can be activated external stimuli to effectively kill tumor cells and eradicate tumors.

  7. Tumor Antigen

  8. Immune responses frequently fail to prevent the growth of tumors • First, tumor cells are derived from host cells. • Second, the rapid growth and spread of tumors • Third, specialized mechanisms for evading host immune responses.

  9. Content 1. General Features 2. Tumor antigen 3. Immune Responses 4. Evasion of Immune Responses 5. Immunotherapy

  10. Tumor Antigen The earliest classification: • Tumor-specific antigen • Tumor-associated antigen

  11. Tumor Antigen • Tumor-specific antigen Antigen that are expressed on tumor cells but not on normal cells were called tumor- specific antigens; some of these antigens are unique to individual tumors, whereas others are shared among tumors of the same type.

  12. Tumor Antigen • Tumor-associated antigen Tumor antigens that are also expressed on normal cells were called tumor-associated antigens; in most cases, these antigens are normal cellular constituents whose expression is aberrant or dysregulated in tumors

  13. Tumor Antigen

  14. Tumor Antigen The modern classification is relies on the molecular structure and source of the antigen

  15. Tumor Antigen

  16. Tumor Antigen

  17. Content 1. General Features 2. Tumor antigen 3. Immune Responses 4. Evasion of Immune Responses 5. Immunotherapy

  18. Immune Responses to Tumors • T lymphocytes • Antibodies • NK cells • Macrophages

  19. Immune Responses to Tumors • T lymphocytes The killing of tumor cells by CD8+ CTL

  20. Immune Responses to Tumors • T lymphocytes

  21. Immune Responses to Tumors • T lymphocytes

  22. Immune Responses to Tumors • Antibodies The killing of tumor cells by activating complement or by ADCC

  23. Immune Responses to Tumors Complement System

  24. Immune Responses to Tumors

  25. Immune Responses to Tumors • NK cells NK cells kill many types of tumor cells,especially cells that have reduces class I MHC expression and can escape killing CTLs.

  26. engagement of inhibitory NK cell receptors such as KIR and CD94/NKG2 by class I MHC molecules delivers an inhibitory signal that counteracts the activation signal.

  27. Immune Responses to Tumors • NK cells

  28. Immune Responses to Tumors • Macrophages Dual role of macrophages in tumor growth and angiogenesis: • They activate and present tumor antigens to T cells, which are then activated to kill tumor cells. • However, tumor cells are often capable of escaping the immune machinery. As the immune surveillance is not sufficient anymore, tumor-associated macrophages contribute to tumor progression.

  29. Content 1. General Features 2. Tumor antigen 3. Immune Responses 4. Evasion of Immune Responses 5. Immunotherapy

  30. Evasion of Immune Responses The key of tumor growth, migration and metastasis is that tumor cells evade immune destruction, often called tumor escape. Turk MJ, J.Exp.Med. 2004, 200(6):771-782 Hori S: Science,2003, 299:1057-1061 Jun Shimizu et al: Nat. Immunology. 2002,3(2): 135-142 Shevach. EM: Nat Rev. Immunol. 2002, 2:389-400

  31. Evasion of Immune Responses • Class I MHC expression may be down-regulated on tumor cells so that they cannot be recognized by CTLs. • Tumor lose expression of antigen that elicit immune responses. • Tumors may fail to induce CTLs because most tumor cells do not express costimulators or class II MHC molecules. • The products of tumor cells may suppress antitumor immune responses. • Tumor antigens may induces may induce specific immunologic tolerance.

  32. Evasion of Immune Responses CD4+CD25+Treg：Negative regulator • Existing a large amount of CD4+CD25+Tregs in TILs • Regrssion the tumorigenesisif deleting the CD4+CD25+Treg Tyler J. Curiel et al: Nature Medicine. 2004, 10(9):942-949 Zhang,L et al: N. Engl. J. Med. 2003, 348:201-213

  33. Content 1. General Features 2. Tumor antigen 3. Immune Responses 4. Evasion of Immune Responses 5. Immunotherapy

  34. Immunotherapy • History Cancer Immunosurveillance Hypothesis (Controversy to Resolution) ‘Inheritable genetic changes must be common in somatic cells and a proportion of these change will represent a step toward malignancy. It is an evolutionary necessity that there should be some mechanism for eliminating or inactivating such potentially dangerous mutant cells and it is postulated that this mechanism is of immunological character’ ----- Sir MacFarlane Burnet, 1964 Fundamental Prediction: Immunodeficient individuals should show a significant increase in tumor incidence. However, ‘Athymic-nude mice and normal mice showed no differences in either latent period or incidence of local sarcomas or lung adenomas within 120 days after administration of 3-methylcholanthrene at birth’ ----- Stutman O, et al. Science 183(4124): 534.1974

  35. 27 years later…. Resolution Immunotherapy • Increased Incidence of MAC-Induced Tumor Detected In Mice With Well-Defined Genetic Immunodeficiencies. Shankaran et al. Nature 410: 1107-1111 2001 • An accumulation of immune cells at tumor sites correlates with improved prognosis. Zhang et al. N Engl J Med 348: 203-213 2003 • First human melanoma tumor antigen (MAGE-1) was identified. T Boon et al. Science, Vol 254, Issue 5038, 1643-1647 1991

  36. Immunotherapy • Active immunotherapy • Passive immunotherapy

  37. Immunotherapy • Active immunotherapy • Vaccination • Augmentation of host immunity to tumors with cytokines and costimulators

  38. Immunotherapy • Active immunotherapy------Vaccination • Killed tumor vaccine • Purified tumor antigens • Professional APC-based vaccines • Cytokine- and costimulator-enhanced vaccines • DNA vaccines • Viral vectors

  39. Immunotherapy

  40. Immunotherapy Dendritic Cell- Based Vaccines Myeloma cell Tumor Biopsy + Vaccine Production Fusion + Leukapheresis Dendritic Cells Tumor Idiotype Protein As tumor specific- antigen Immunization with Antigen-pulsed DCs Co-culture Regression of Lymphoma following vaccination with Id-pulsed DC Levy R, Englman E, et al. Blood 2002, 90: 1517-1526

  41. Immunotherapy Augmentation of host immunity to tumors

  42. Immunotherapy • Passive immunotherapy • Adoptive Cellular Therapy • Anti-tumor Antibodies

  43. Immunotherapy Adoptive cellular therapy

  44. Immunotherapy Anti-tumor Antibodies Her-2/Neu, CD20, CD10, CEA, CA-125, GD3 ganglioside

  45. Key notes • Concepts: TSA, TAA • Evasion of immune responses by tumors • Immunotherapy to tumors

  46. DEPARTMENT OF IMMUNOLOGY Thank you!

More Related